Dogwood Therapeutics, Inc.
DWTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.96M
Close$
$0.77
49.1% downside
Current Fair Value
49.1% downsideOvervalued by 49.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.96 Million |
|---|---|
| Enterprise Value | $-10,111,074.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.32 |
| Beta | 1.71 |
| Outstanding Shares | 33,544,748 |
Return
| Return on Equity | 15059.05% |
|---|---|
| Return on Assets | 12752.22% |
| Return on Invested Capital | -21239.62% |
Valuation & Multiples
| P/E Ratio | -0.15 |
|---|---|
| PEG | 0.15 |
| Price to Sales | - |
| Price to Book Ratio | 0.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.79%▲ 10.31% |
|---|---|
| Total Invested | $7.64M▲ 2515.70% |
| Investors Holding | 13▲ 3.00% |
ESG Score
No data
About Dogwood Therapeutics, Inc.
12 employees
CEO: Gregory Duncan Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate...